Skip to content

D&A at other companies

ResMed logo
ResMedRMD
$7.85M+5.5%
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
$388K+11.5%
Savara logo
SavaraSVRA
$24K-20.0%

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-9.7%
Enterprise value$98.45M-9.5%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inogen's D&A?
Inogen (INGN) reported D&A of $4.9M in Q1 2026.
How has Inogen's D&A changed year-over-year?
Inogen's D&A decreased by 5.5% year-over-year, from $5.19M to $4.9M.
What is the long-term trend for Inogen's D&A?
Over 4 years (2021 to 2025), Inogen's D&A has grown at a 1.3% compound annual growth rate (CAGR), from $17.27M to $18.17M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.